Wockhardt Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Wockhardt Limited Pharmaceutical Export Portfolio Dataset — 10 Products, $44.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Wockhardt Limited — Pharmaceutical Exporter Profile (2026) | 10 Products, $44.5M Trade | TransData Nexus

Wockhardt Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $44.5M Total Trade · DGFT Verified

Wockhardt Limited is an Indian pharmaceutical exporter with a total trade value of $44.5M across 10 products in 7 therapeutic categories. Based on 895 verified export shipments from Indian Customs (DGFT) records, Wockhardt Limited is the #1 Indian exporter in 2 products including Insulin, Codeine. Top exports include Insulin ($22.7M), Codeine ($9.6M), Levothyroxine ($5.2M).

Wockhardt Limited — Export Portfolio & Destination Treemap

Wockhardt Limited pharmaceutical export portfolio — 10 products across 7 therapeutic categories. Source: Indian Customs (DGFT).

Who is Wockhardt Limited? — Company Overview & Market Position

Wockhardt Limited, established in 1967 by Dr. Habil F. Khorakiwala, is a leading Indian pharmaceutical and biotechnology company headquartered in Mumbai, Maharashtra. The company specializes in the development, manufacture, and marketing of pharmaceutical formulations, biopharmaceuticals, vaccines, and active pharmaceutical ingredients (APIs). Wockhardt operates globally, with a significant presence in the United States, United Kingdom, Ireland, France, and other international markets.

As of March 2026, Wockhardt Limited employs approximately 2,296 individuals. The company's stock is listed on the National Stock Exchange of India under the ticker symbol WOCKPHARMA. In the fiscal year ending March 2025, Wockhardt reported revenues of $360 million, reflecting a 7.6% increase from the previous year.

What Does Wockhardt Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Insulin$22.7M 2Codeine$9.6M

Product Portfolio — Top 10 by Export Value

Wockhardt Limited exports 10 pharmaceutical products across 7 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Insulin	Diabetes & Endocrine	$22.7M	454	29.9%	1
2	Codeine	Analgesics & Antipyretics	$9.6M	191	8.7%	1
3	Levothyroxine	Diabetes & Endocrine	$5.2M	103	6.6%	4
4	Ibuprofen	Analgesics & Antipyretics	$2.6M	53	0.5%	6
5	Prednisolone	Respiratory	$2.6M	53	2.8%	3
6	Folic	Nutritional Supplements	$800.0K	16	1.4%	13
7	Tamoxifen	Advanced Oncology	$409.8K	9	2.8%	6
8	Colchicine	Lipid & Metabolism	$338.8K	10	1.6%	11
9	Melatonin	Nutritional Supplements	$150.0K	3	1.6%	7
10	Vati	Ayurvedic & Herbal Products	$150.0K	3	0.6%	15

Wockhardt Limited exports 10 pharmaceutical products across 7 therapeutic categories with a total export value of $44.5M. The company is the #1 Indian exporter in 2 products: Insulin, Codeine. The top category is Diabetes & Endocrine (62.5% of portfolio), followed by Analgesics & Antipyretics (27.4%), indicating a concentrated portfolio with the top 5 products accounting for 95.9% of total export value.

Wockhardt Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Wockhardt Limited operates multiple manufacturing facilities across India, the United States, the United Kingdom, and Europe. In India, the company has state-of-the-art plants in Aurangabad, Baddi, and Chikalthana, specializing in the production of various pharmaceutical formulations and APIs. The UK facility in Wrexham, North Wales, is notable for its advanced vaccine manufacturing capabilities, including the production of COVID-19 vaccines.

In the United States, Wockhardt USA LLC operates a manufacturing plant in Morton Grove, Illinois, acquired in 2007. This facility focuses on the production of oral liquids and topicals, serving the U.S. market.

3Key Leadership

The leadership team at Wockhardt Limited is headed by Dr. Habil F. Khorakiwala, the Founder and Executive Chairman, who established the company in 1967. Dr. Murtaza Habil Khorakiwala serves as the Managing Director and Executive Director, overseeing the company's strategic direction and operations. Dr. Huzaifa Habil Khorakiwala holds the position of Executive Director, contributing to the company's growth and development.

Other key executives include Deepak R. Madnani, the Chief Financial Officer, who manages the company's financial strategies, and Dr. Sachin Bhagwat, the Chief Scientific Officer, leading research and development initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Wockhardt Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Wockhardt Limited has established a strong presence in several regulated markets, including the United States, the United Kingdom, and Europe. In the U.S., the company operates through its subsidiary, Wockhardt USA LLC, which has received over 110 Abbreviated New Drug Application (ANDA) approvals from the U.S. Food and Drug Administration (FDA). The Morton Grove facility in Illinois, acquired in 2007, produces oral liquids and topicals for the U.S. market.

In the United Kingdom, Wockhardt UK Ltd is among the top five generic companies, holding a significant market share in both retail and hospital segments. The company's manufacturing facility in Wrexham, North Wales, is equipped with advanced technologies and has been a key contributor to the global fight against COVID-19, producing millions of vaccine doses.

Wockhardt's European operations include a manufacturing facility in Ireland, which has been instrumental in supplying pharmaceutical products to the European market. The company's strategic acquisitions, such as the purchase of CP Pharmaceuticals in the UK and Pinewood Laboratories in Ireland, have bolstered its presence in these regulated markets.

2Emerging Markets

Wockhardt Limited has made significant inroads into emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's focus on diabetes, biosimilars, and branded generics has facilitated its expansion in these regions. Wockhardt's vaccine manufacturing facility in Wrexham, UK, has been a key contributor to the global fight against COVID-19, producing millions of vaccine doses.

Wockhardt Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Wockhardt Limited's subsidiary, Wockhardt USA LLC, has a robust relationship with the U.S. Food and Drug Administration (FDA). The company has received over 110 Abbreviated New Drug Application (ANDA) approvals, indicating a strong portfolio of generic pharmaceutical products. The Morton Grove facility in Illinois, acquired in 2007, is registered with the FDA and produces oral liquids and topicals for the U.S. market.

Wockhardt's commitment to quality and regulatory compliance is evident in its adherence to FDA standards. The company's facilities are subject to regular FDA inspections, ensuring that manufacturing practices meet the agency's stringent requirements. Wockhardt's proactive approach to addressing any observations or concerns raised during inspections reflects its dedication to maintaining high-quality standards in its U.S. operations.

2WHO & EU GMP

Wockhardt Limited's manufacturing facilities adhere to Good Manufacturing Practice (GMP) standards set by the World Health Organization (WHO) and the European Union (EU). The company's vaccine manufacturing facility in Wrexham, UK, is WHO prequalified, enabling it to supply vaccines to international markets.

In Europe, Wockhardt's manufacturing facility in Ireland complies with EU GMP standards, ensuring that its pharmaceutical products meet the quality requirements for distribution within the European Union. The company's commitment to maintaining these certifications underscores its dedication to producing high-quality pharmaceutical products for global markets.

Wockhardt Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Wockhardt Limited operates in a competitive pharmaceutical industry, facing competition from both multinational corporations and domestic companies. In the generic pharmaceutical segment, the company competes with firms such as Cipla, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries, which have established global and domestic market presences.

In the vaccine manufacturing sector, Wockhardt faces competition from companies like Serum Institute of India and Bharat Biotech, which are also involved in the production of vaccines for global markets. Wockhardt's strategic acquisitions, such as the purchase of CP Pharmaceuticals in the UK and Pinewood Laboratories in Ireland, have bolstered its position in these competitive markets.

2Key Differentiators

Wockhardt Limited's key differentiators include its strong focus on research and development, particularly in the area of antibiotics and biopharmaceuticals. The company's commitment to innovation is evident in its development of novel antibiotics and biosimilars, addressing critical healthcare needs.

Additionally, Wockhardt's global manufacturing capabilities, including WHO prequalified facilities and adherence to EU GMP standards, enable it to supply high-quality pharmaceutical products to international markets.

TransData Nexus Research · DGFT export records, industry analysis

Frequently Asked Questions — Wockhardt Limited

How many pharmaceutical products does Wockhardt Limited export from India?

Wockhardt Limited exports 10 pharmaceutical products across 7 therapeutic categories. The top exports are Insulin ($22.7M), Codeine ($9.6M), Levothyroxine ($5.2M), Ibuprofen ($2.6M), Prednisolone ($2.6M). Total export value is $44.5M.

What is Wockhardt Limited's total pharmaceutical export value?

Wockhardt Limited's total pharmaceutical export value is $44.5M, based on 895 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Wockhardt Limited the #1 Indian exporter?

Wockhardt Limited is the #1 Indian exporter in 2 products: Insulin (29.9% market share), Codeine (8.7% market share).

What therapeutic categories does Wockhardt Limited cover?

Wockhardt Limited exports across 7 therapeutic categories. The largest are Diabetes & Endocrine (62.5%, 2 products), Analgesics & Antipyretics (27.4%, 2 products), Respiratory (5.9%, 1 products).

Get Full Wockhardt Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.